MapLight Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-161.15	-77.58
Depreciation & Amortization	0.58	0.7
Stock-Based Compensation	36.01	1.08
Other Adjustments	-0.73	0.05
Changes in Accounts Payable	1.38	-1.35
Changes in Accrued Expenses	2.9	2.17
Changes in Other Operating Activities	-17.12	-3.89
Operating Cash Flow	-138.14	-78.82
Capital Expenditures	-0.47	-0.77
Purchases of Investments	-408.23	-125.02
Proceeds from Sale of Investments	85.5	45
Investing Cash Flow	-323.21	-80.79
Issuance of Common Stock	276	0.29
Net Common Stock Issued (Repurchased)	276	0.29
Issuance of Preferred Stock	198.84	119.96
Net Preferred Stock Issued (Repurchased)	198.84	119.96
Other Financing Activities	-5.02	-2.19
Financing Cash Flow	469.82	118.06
Net Cash Flow	8.48	-41.54
Free Cash Flow	-138.61	-79.59
Free Cash Flow Per Share	-15.97	-108.11
Levered Free Cash Flow	-173.88	-80.71
Unlevered Free Cash Flow	-181.81	-86.08

SEC Filings: 10-K · 10-Q